Eurofarma Laboratorios S.A.

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

8 drugs in development

Phase 38

By Therapeutic Area

top 2

Respiratory

450%

Cardiovascular

225%

R&D Momentum

64/100

Pipeline Velocity

39/100

Trial Completion Rate

55/100

Pipeline Concentration

38/100

Pipeline Freshness

100/100

Strategic Signals

↗Mature portfolio may be looking to in-license early assets
↗Active in Cardiovascular but thin pipeline — potential licensing opportunity

Activity

Key Events

Jun 1, 2026TrialNon-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil

May 30, 2026TrialFixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil

Apr 1, 2026TrialEfficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy

Apr 1, 2026TrialA Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight

Mar 1, 2026TrialParallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil

Mar 1, 2026TrialStudy of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris

Mar 26, 2025TrialPhase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment

Jul 8, 2024TrialFixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children

4 more events

Mar 27, 2024TrialFixed-dose Combination of Oxycodone [OXIcodona] + IbuproFEN in Pain Relief After Third Molar Extraction

Nov 8, 2023TrialFixed Dose Combination of COdeine + DIpyrone to Mitigate Moderate to Intense Pain Post-impacted Third Lower Molar Extraction

Apr 19, 2023TrialA Multicenter, Randomized, Parallel, Two-period, Non-inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment

Mar 2, 2023TrialTreatment of Androgenetic Alopecia in Men for 24 Weeks

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

2 patent groups across drugs · Source: FDA Orange Book

DrugExpires

SynalarAug 12, 2027 Synalar2 patentsJan 12, 2028

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

N0877Phase 3

Respiratory

Asthma

AleniaPhase 3

N0783Phase 3

Chronic Obstructive Pulmonary Disease

Comparator - TrimbowPhase 3

Fluticasone /Formoterol /GlycopyrroniumPhase 3

Unknown / Other

Benign Prostatic Hyperplasia

N0728Phase 3

VesomniPhase 3

Regulatory

Regulatory Timeline

19825 events

FDADec 30

Loprox — LOPROX

Application NDA018748 (NDA)

FDAJan 1

Synalar — SYNALAR-HP

Application NDA016161 (NDA)

FDAJan 1

Synalar — SYNALAR

Application NDA013960 (NDA)

FDAJan 1

Synalar — SYNALAR

Application NDA012787 (NDA)

FDAJan 1

Synalar — SYNALAR

Application NDA015296 (NDA)

19881 event

FDADec 30

Loprox — LOPROX

Application NDA019824 (NDA)

19901 event

FDAAug 27

Synalar — CAPEX

Application NDA020001 (NDA)

19971 event

FDAJul 21

Loprox — CICLOPIROX

Application NDA020519 (NDA)

19991 event

FDADec 17

Loprox — PENLAC

Application NDA021022 (NDA)

20031 event

FDAFeb 28

Loprox — LOPROX

Application NDA021159 (NDA)

20052 events

FDANov 9

Synalar — DERMOTIC

Application NDA019452 (NDA)

FDAApr 8

Synalar — RETISERT

Application NDA021737 (NDA)

20141 event

FDASep 26

Synalar — ILUVIEN

Application NDA201923 (NDA)

20181 event

FDAOct 12

Synalar — YUTIQ

Application NDA210331 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)